Newswise — An international study led by scientists at McGill University reports, for the first time, that drugs that selectively target the melatonin MT2 receptor represent a novel class of analgesic drugs that could be used to treat patients with neuropathic pain.

Neuropathic pain is a disorder characterized by severe pain that sometimes develops following nerve damage resulting from conditions such as shingles, injury, amputation, autoimmune inflammation and cancer. It is a permanent pain that persists for months or years.

An estimated 7% to 8% of adults worldwide suffer from neuropathic pain, with 5% of cases considered severe. The problem has significant economic implications, including reduced productivity and substantial health care costs.

Melatonin, a neurohormone present in mammals, acts on the brain by activating two receptors called “MT1” and “MT2” that are responsible for regulating several functions including sleep, depression, anxiety and circadian rhythms.

Now, a team led by Dr. Gabriella Gobbi, Associate Professor in the Department of Psychiatry of McGill’s Faculty of Medicine, has demonstrated that UCM924, a melatonin MT2 receptor drug, relieves chronic pain in animal models; the team has also identified the drug’s mechanism of action in the brain. UCM924, by activating the MT2 receptors in the periaqueductal grey (a brain area controlling pain), is able to switch off the neurons that trigger pain and switch on the ones that turn off pain The findings are reported in the February issue of the journal PAIN.

“There are very limited treatments available for neuropathic pain, and a lot of patients use opioids,” says Dr. Gobbi, who is also a researcher at the Research Institute of the McGill University Health Centre (RI-MUHC). “In the long term, these can lead to addiction and severe side effects, including dependence and tolerance, opioid-induced hyperalgesia (the pain becomes even worse), and risk of death. For these reasons, identifying novel analgesics is of keen interest in the medical field today.”

Previous studies have shown that over-the-counter melatonin has very limited effect. Dr. Gobbi and her team demonstrated that this is because exogenous melatonin activates both MT1 and MT2 receptors, which have conflicting and opposite effects.

In the course of their work to investigate the efficacy of MT2 receptor drugs for insomnia, the researchers discovered that UCM924 also soothes neuropathic pain at lower doses. This suggests that these drugs could offer relief both to people who suffer from pain during the day, using low doses, and from insomnia at night, using higher doses. At least 50-70% of patients with neuropathic pain conditions complain of significant sleep disturbance, and this new study unveils how the mechanisms of pain and sleep are closely related.

The research team is now looking for partners interested in pursuing clinical development and eventual commercialization of these novel drugs. Scientists from University Veracruzana (Mexico), the Second University of Naples (Italy), the Scuola Superiore Sant’Anna (Italy), the University of Milan (Italy), University Carlo Bo (Italy), and Cinvestav-Sede Sur (Mexico) also contributed to this study.

The research was supported by the Canadian Institutes of Health Research, Le Fonds de recherche du Québec - Santé, the Canadian Foundation for Innovation and the Ministère de l'Économie, de l'Innovation et des Exportations.

"Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways" Martha Lopez-Canul, Enza Palazzo, Sergio Dominguez-Lopez, Livio Luongo, Baptiste Lacoste, Stefano Comai, Debora Angeloni, Franco Fraschini, Serena Boccella, Gilberto Spadoni, Annalida Bedini, Giorgio Tarzia, Sabatino Maione, Vinicio Granados-Soto, Gabriella Gobbi., Pain. 2015 Feb; 156(2):305-17. doi: 10.1097/01.j.pain.0000460311.71572.5f.

More from the lab of Dr. Gobbi: